SureGene, Medco Research Partner on PGx Study for Antipsychotic Drugs | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — SureGene and Medco Research Institute today announced a pharmacogenomic collaboration to test whether genetic variations can help predict response to widely prescribed antipsychotic drugs.

SureGene and MRI, a wholly-owned subsidiary of Medco Health Solutions, will conduct a prospective study to investigate biomarkers previously identified by SureGene, and validate their utility as predictors of efficacy and safety for drugs prescribed to patients with mental illnesses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.